I earned my PhD in Kinesiology & Health Science at York University working under the supervision of Dr. Olivier Birot. My doctoral research investigated skeletal muscle microvascular adaptability in health and disease, with a special interest on molecular factors regulating capillary growth and/or regression in response to both physiological (exercise) and pathological (diabetes) stimuli. My current post-doctoral research aims to improve our understanding of the biology of somatostatin receptor type 2 (SSTR2) antagonism to prevent hypoglycemia using animal models of type 1 diabetes, ultimately setting the stage for phase 1 and 2 clinical studies in humans. In my free time, I enjoy playing and watching basketball, going to the gym, playing guitar, and travelling.
I completed my MSc in Kinesiology & Health Science at York University under the supervision of Dr. Anthony Scimè. Currently, I am investigating the effects of sodium glucose co-transporter-2 (SGLT-2) inhibitors and somatostatin receptor type 2 (SSTR2) antagonists on glucose counterregulation in type 1 diabetes for improving hypoglycemia prevention. Outside of the lab, I enjoy travelling, cooking, reading, and trying new foods.
MSc Year 3
I completed my BSc in Biomedical Science at York University and am excited to continue my education in Dr. Riddell’s lab as an MSc candidate. My research focuses on the efficacy of carbohydrate feeding and insulin modifications for the prevention of hypoglycemia during prolonged aerobic exercise in individuals with type 1 diabetes. In my spare time, I enjoy hockey, soccer, baking, and travelling.
MSc Year 1
I received a BSc in Biology from the University of Guelph and a BA in Kinesiology & Health Science from York University. Joining the Riddell Lab as an undergraduate student, I collaborated with a biotechnology company to develop a protocol for the extraction and quantification of pancreatic hormones. I continued in the lab as a research assistant and now graduate student, investigating somatostatin as a hormonal mediator of counterregulatory dysfunction in type 2 diabetes. To help alleviate the disease burden, I am evaluating the therapeutic potential of somatostatin receptor type-2 antagonists (SSTR2a) for the prevention of hypoglycemia in diabetic individuals. In my free time, I enjoy playing ultimate frisbee and watching Jeopardy.